FDA Approves Fotivda

FDA Approves Fotivda

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma BOSTON–(BUSINESS WIRE) March 10, 2021 — AVEO…

Read More
FDA Approves Pepaxto

FDA Approves Pepaxto

FDA Approves Pepaxto (melphalan flufenamide) for Patients with Relapsed or Refractory Multiple Myeloma STOCKHOLM, Feb. 26, 2021 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO),…

Read More
APO-Adefovir

APO-Adefovir

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APO-Adefovir Tablets Contains the active ingredient adefovir (as adefovir dipivoxil) Consumer Medicine…

Read More
APOHEALTH Sleep Assist

APOHEALTH Sleep Assist

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APOHEALTH SLEEP ASSIST Contains the active ingredient doxylamine succinate Consumer Medicine Information…

Read More
Imogam

Imogam

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. IMOGAM RABIES pasteurized® Human rabies immunoglobulin Consumer Medicine Information What is in…

Read More
Biaxsig

Biaxsig

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. BIAXSIG®   Consumer Medicine Information (CMI) summary The full CMI on the…

Read More
Hiprex

Hiprex

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. HIPREX™ TABLETS Hexamine hippurate Consumer Medicine Information What is in this leaflet…

Read More